Clinical features and mutations in patients with dominant retinitis pigmentosa-1 (RP1).
Eliot L. Berson(Massachusetts Eye and Ear Infirmary), Thaddeus P. Dryja(Massachusetts Eye and Ear Infirmary), Eric A. Pierce(Broad Institute), S. M. Adams(California Institute of Technology), Jonna Grimsby(Broad Institute), Michael A. Sandberg(Centre For Human Genetics), Terri L. McGee, Elizabeth A. Sweklo(Massachusetts Eye and Ear Infirmary)
PubMed
September 1, 2001
Cited by 77
Related Papers
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
The Zwicky Transient Facility: System Overview, Performance, and First Results
|Publications of the Astronomical Society of the Pacific|2018|2.1k
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
|Proceedings of the National Academy of Sciences|1995|1.3k
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
|Proceedings of the National Academy of Sciences|1995|1k